The aforementioned results prove that inhibiting the PKP3/MAPK/ERCC1 axis can facilitate the development of therapeutic strategy against PCOS with PDS, but the correlation between PKP3 and ERCC1 still requires subsequent endeavors due to the limited data to support it. This evidence concerns the gene ERCC1 and polycystic ovary syndrome.